Sequential therapy in renal cell carcinoma.

  title={Sequential therapy in renal cell carcinoma.},
  author={Bernard Escudier and Marine Gross Goupil and Christophe C Massard and Karim S Fizazi},
  volume={115 10 Suppl},
Because of the recent approval of several drugs for the treatment of renal cell carcinoma (including sorafenib, sunitinib, temsirolimus, and, in Europe, bevacizumab plus interferon), the use of sequential therapy has become routine practice. There is now evidence that administering these targeted agents sequentially provides clinical benefit by inducing tumor shrinkage and prolonged progression-free survival (PFS) in a large number of patients. However, data regarding overall survival (OS) are… CONTINUE READING
36 Citations
20 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 36 extracted citations


Publications referenced by this paper.
Showing 1-10 of 20 references

Axitinib (AG013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib [abstract

  • BI Rini, GT Wilding, G Hudes
  • J Clin Oncol
  • 2007
Highly Influential
6 Excerpts

Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract

  • PH Patel, RS Chadalavada, NM Ishill
  • J Clin Oncol. 2008;26(suppl): Pages. Abstract…
  • 2009

Overall survival with sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract

  • R Figlin, TE Hutson, P Tomczak
  • J Clin Oncol
  • 2008

Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [abstract

  • RC Whorf, JD Hainsworth, DR Spigel
  • J Clin Oncol
  • 2008
1 Excerpt

Retrospective analysis of interleukin - 2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy [ abstract ]

  • T Schwarzberg, MM Regan, V Liu
  • J Clin Oncol
  • 2008

Similar Papers

Loading similar papers…